ClinicalTrials.gg
Active, not recruitingNCT04280029SELUTION4ISRUpdated Oct 20, 2026Results posted

SELUTION SLR™ 014 In-stent Restenosis

An interventional study of SELUTION SLR 014 DEB and Standard of Care in Coronary Restenosis, sponsored by M.A. Med Alliance S.A.. Active, not recruiting at 48 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by M.A. Med Alliance S.A. · Not applicable, Interventional, and Treatment

How we know

Updated Oct 20, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
418
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Coronary Restenosis with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Coronary Restenosis · United States.

Enrollment
11th of 19
418 · median 480
Started
2020
with 1 other
No phase
7 of 30
none open now
Registered
28th of 30
by date
Lead sponsor
1 of 30
M.A. Med Alliance S.A.

Among the 30 studies in Coronary Restenosis with a site in United States, this one is the 11th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2020, is one of 7 with no phase, and was the 28th registered.

Coronary Restenosis

107 studies on the registry are indexed under Coronary Restenosis; 10 are open to participants now.

Browse Coronary Restenosis studies →

Open to participants now

1 of the 30 studies in Coronary Restenosis with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Coronary Restenosis studies recruiting now, 7 set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Coronary Restenosis with a site in United States, or all of them as a file.
02

Study summary

Prospective, multi-center, randomized, single blind, controlled, noninferiority clinical trial.

Subjects with previous bare-metal stent (BMS) or Drug-Eluting Stent (DES) and qualifying evidence for In-stent Restenosis (ISR) will be screened per the protocol inclusion and exclusion criteria. Eligible subjects will be randomized 1:1 to treatment with either the SELUTION SLR 014 DEB or Standard of Care (SOC) to include contemporary DES (zotarolimus-eluting stents [ZES] and everolimus-eluting stents [EES] only) or Balloon Angioplasty (BA). A maximum of 20% of patients randomized to SOC will be treated with BA.

The primary endpoint will be Target Lesion Failure (TLF) at 12-months in the SOC group vs. the SELUTION SLR 014 DEB in all patients.

Read the detailed description

Prospective, multi-center, randomized, single blind, controlled, noninferiority clinical trial will enroll up to 418 randomized subjects (including up to 60 subjects in an angiographic and optical coherence tomography [OCT] sub-study) at up to 80 sites in the United States (US), Canada, Brazil, and Europe (EU). A minimum of 50% of the subjects will be enrolled in the US.

Subjects with previous bare-metal stent (BMS) or Drug-Eluting Stent (DES) and qualifying evidence for ISR will be screened per the protocol inclusion and exclusion criteria. Eligible subjects will be randomized 1:1 to treatment with either the SELUTION SLR 014 DEB or SOC to include contemporary DES (zotarolimus-eluting stents [ZES] and everolimus-eluting stents [EES] only) or BA. A maximum of 20% of patients randomized to SOC will be treated with BA.

The primary endpoint will be Target Lesion Failure (TLF) at 12-months in the SOC group vs. the SELUTION SLR 014 DEB group.

A subset of up to 60 subjects will be enrolled in the angiographic and OCT sub-study and undergo planned angiographic and OCT follow-up within 30 days after completion of the 12-month primary endpoint clinical follow-up/assessment.

03

Conditions studied

  • Coronary Restenosis

Browse trials for

Keywords

  • In-stent restenosis
  • Drug Eluting Balloon
  • Coronary
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Clinical Inclusion Criteria:

  1. Subject age is ≥ 18 years or minimum legal age as required by local regulations.
  2. Female subjects of have a negative pregnancy test ≤ 7 days before the procedure.
  3. Subject presents with chronic coronary syndrome (CCS) (manifest as documented angina or positive functional testing), unstable angina or stabilized non-ST-elevation myocardial infarction (NSTEMI) (biomarkers stabilized or down trending) with an indication for percutaneous coronary intervention (PCI) and planned intervention.
  4. Subject is eligible for dual antiplatelet therapy (DAPT) treatment with aspirin plus either Clopidogrel, Prasugrel, or Ticagrelor. Note: Subjects who require continued oral anticoagulant therapy my omit aspirin at discretion of investigator.
  5. >1 year in opinion of investigator.
  6. Subject is willing and able to provide and comply with study procedures and required follow-up evaluations.

Angiographic Inclusion Criteria

  1. Target lesion is within a native coronary artery or major branch.
  2. Target lesion is within a previously placed BMS or DES and does not extend further than 5 mm beyond either the proximal or distal edge of the stent.
  3. Up to two (2) non-target lesions in non-target vessels may be treated, but successful PCI of the non-target lesions must be completed before treatment of the target lesion. Successful treatment is defined as no greater than 30% residual stenosis by visual estimate, no dissection greater than National Heart, Lung, Blood Institute (NHLBI) type C, and Thrombolysis in Myocardial Infarction (TIMI) grade flow in the non-target lesion > 2.
  4. Target lesion is ≤ 26 mm in length.
  5. Target lesion has diameter stenosis of > 50% and ≤ 99% by visual estimate.
  6. Reference vessel diameter (RVD) is ≥ 2.00 mm and ≤ 4.50 mm.
  7. Target lesion must be successfully pre-dilated/pre-treated. Note: Successful pre-dilation/pre-treatment is defined as dilation or pre-treatment that achieves stent expansion of approximately 80% of the distal RVD (at the discretion of the investigator) based on intravascular ultrasound (IVUS)/optical coherence tomography (OCT) and no greater than 30% residual stenosis by visual estimate and no dissection greater than NHLBI type C. TIMI grade flow in the target lesion must be > 2. Note: Atherectomy and cutting balloon are permitted for pre-treatment.

Clinical Exclusion Criteria:

  1. Known or allergy to Sirolimus or other pharmacologic agents required for the procedure.
  2. ST-elevation myocardial infarction (STEMI) within 30 days.
  3. Planned treatment of additional lesions in the target vessel, or more than two (2) non-target lesions within non-target vessels, during the index procedure.
  4. Target lesion is located within a bifurcation with planned treatment of side branch vessel.
  5. Target lesion is the 3rd or greater stent failure (i.e., more than two [2] layers of stent are present at any segment of the target lesion).
  6. Target vessel had any previous vascular brachytherapy treatment or is planned to undergo brachytherapy at index procedure.
  7. Previous PCI of the target vessel within 30 days.
  8. Planned PCI of a non-target vessel, or a non-target lesion in the target vessel, within 30 days of randomization.
  9. Subject has chronic renal insufficiency (dialysis dependent, or [GFR] ≤ 30 ml/min/1.73 m² within 30 days of index procedure) or has undergone renal transplantation.
  10. Subject has acute renal insufficiency confirmed by 50% increase of serum creatinine within 48 hours before procedure and/or decrease in urine output.
  11. History of active peptic ulcer or gastrointestinal bleeding within prior 6 months or other inability to comply with recommended duration of DAPT.
  12. Subject is pregnant, breast-feeding, or a woman of childbearing potential who is not using appropriate to avoid becoming pregnant.
  13. Documented (LVEF) \< 25%.
  14. Currently participating in another drug or device study that has not completed primary endpoint follow-up.

Angiographic Exclusion Criteria

  1. Target lesion is a total occlusion or has evidence of thrombus.
  2. Target lesion involves an unprotected left main.
  3. Target lesion has > 30% residual stenosis by visual estimate or dissection greater than NHLBI type C after pre-dilation/pre-treatment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
418 participants (actual)

Study arms

  • Experimental
    SELUTION SLR 014 DEB

    The SELUTION Sustained Limus Release (SLR)™ 014 drug-eluting balloon (DEB) catheter is a combination product consisting of a standard percutaneous transluminal angioplasty (PTA) balloon catheter coated with a drug (Sirolimus).

    Device: SELUTION SLR 014 DEB

  • Active comparator
    Standard Of Care

    Plain Old Balloon Angioplasty (POBA) or FDA-approved commercially available -limus eluting Drug-Eluting Stent (DES)

    Device: Standard of Care

Interventions

  • DeviceSELUTION SLR 014 DEB

    The SELUTION Sustained Limus Release (SLR)™ 014 drug-eluting balloon (DEB) catheter is a combination product consisting of a standard percutaneous transluminal angioplasty (PTA) balloon catheter coated with a drug (Sirolimus).

  • DeviceStandard of Care

    POBA or FDA-approved commercially available -limus eluting DES

06

What researchers measure

Primary outcomes

  1. Number of Participants With Target Lesion Failure (TLF)

    TLF is defined as all cardiac death, target vessel myocardial infarction (MI) or clinically driven Target Lesion Revascularization (TLR). MI includes spontaneous (Type 1) MI using the 4th Universal Definition of Myocardial Infarction (UDMI) and peri-procedural MI using the Society for Cardiac Angiography and Intervention (SCAI) definition.

    Time frame: 12 months post-index procedure

Secondary outcomes

  1. Device Success

    Time frame: Index Procedure

  2. Lesion Success

    Time frame: Index Procedure

  3. Procedure Success

    Time frame: Index Procedure

  4. Composite Safety Endpoint

    Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

  5. Clinically Driven Target Vessel Revascularization (TVR), All TVR, Non-TVR

    Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

  6. TLF

    Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

  7. Target Vessel Failure (TVF)

    Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

  8. Net Adverse Clinical Events

    Time frame: Prior to discharge, at 1, 6, and 12 months

  9. Binary Angiographic Restenosis

    Time frame: 12 months

  10. In-stent Percent Diameter Stenosis

    Time frame: 12 months

  11. In-segment Percent Diameter Stenosis

    Time frame: 12 months

  12. In-stent Late Lumen Loss (LLL)

    Time frame: 12 months

  13. In-segment LLL

    Time frame: 12 months

  14. In-stent Minimum Lumen Diameter (MLD)

    Time frame: 12 months

  15. In-segment MLD

    Time frame: 12 months

  16. Optical Coherence Tomography (OCT) Assessment of Neointimal Hyperplasia, Neo-atherosclerosis, and Stent Malapposition

    Time frame: 12 months

  17. TLF

    SELUTION SLR 014 DEB versus DES among participants with one previous layer of stent

    Time frame: 12 months

  18. Clinically-driven TLR

    Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

  19. All-cause Mortality

    Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

  20. Cardiovascular Mortality

    Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

  21. MI

    Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

  22. All TLR

    Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

  23. Stent Thrombosis

    Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

  24. Bleeding

    Time frame: Prior to discharge, at 1, 6, and 12 months

Other outcomes

  1. Cardiac Biomarker Elevations

    Time frame: Peri-Procedural

07

Results

Posted Oct 20, 2026

Participant flow

Participant flow — Overall Study
MilestoneSELUTION SLR 014 DEBStandard Of Care
Started210208
Completed197199
Not completed139
Withdrew: Withdrawal by subject11
Withdrew: Death95
Withdrew: Lost to follow-up10
Withdrew: Site closing & voluntarily withdrawing and withdrawal with continued emr and public records review23

Outcome measures

PrimaryNumber of Participants With Target Lesion Failure (TLF)

TLF is defined as all cardiac death, target vessel myocardial infarction (MI) or clinically driven Target Lesion Revascularization (TLR). MI includes spontaneous (Type 1) MI using the 4th Universal Definition of Myocardial Infarction (UDMI) and peri-procedural MI using the Society for Cardiac Angiography and Intervention (SCAI) definition.

Time frame:
12 months post-index procedure
Reported as:
Count of participants · Participants
Number of Participants With Target Lesion Failure (TLF)
ParticipantsSELUTION SLR 014 DEBStandard Of Care
Number of Participants With Target Lesion Failure (TLF)3228
SecondaryDevice Success
Time frame:
Index Procedure

Results for this outcome have not been posted.

SecondaryLesion Success
Time frame:
Index Procedure

Results for this outcome have not been posted.

SecondaryProcedure Success
Time frame:
Index Procedure

Results for this outcome have not been posted.

SecondaryComposite Safety Endpoint
Time frame:
Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

Results for this outcome have not been posted.

SecondaryClinically Driven Target Vessel Revascularization (TVR), All TVR, Non-TVR
Time frame:
Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

Results for this outcome have not been posted.

SecondaryTLF
Time frame:
Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

Results for this outcome have not been posted.

SecondaryTarget Vessel Failure (TVF)
Time frame:
Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

Results for this outcome have not been posted.

SecondaryNet Adverse Clinical Events
Time frame:
Prior to discharge, at 1, 6, and 12 months

Results for this outcome have not been posted.

SecondaryBinary Angiographic Restenosis
Time frame:
12 months

Results for this outcome have not been posted.

SecondaryIn-stent Percent Diameter Stenosis
Time frame:
12 months

Results for this outcome have not been posted.

SecondaryIn-segment Percent Diameter Stenosis
Time frame:
12 months

Results for this outcome have not been posted.

SecondaryIn-stent Late Lumen Loss (LLL)
Time frame:
12 months

Results for this outcome have not been posted.

SecondaryIn-segment LLL
Time frame:
12 months

Results for this outcome have not been posted.

SecondaryIn-stent Minimum Lumen Diameter (MLD)
Time frame:
12 months

Results for this outcome have not been posted.

SecondaryIn-segment MLD
Time frame:
12 months

Results for this outcome have not been posted.

SecondaryOptical Coherence Tomography (OCT) Assessment of Neointimal Hyperplasia, Neo-atherosclerosis, and Stent Malapposition
Time frame:
12 months

Results for this outcome have not been posted.

SecondaryTLF

SELUTION SLR 014 DEB versus DES among participants with one previous layer of stent

Time frame:
12 months

Results for this outcome have not been posted.

Other pre-specifiedCardiac Biomarker Elevations
Time frame:
Peri-Procedural

Results for this outcome have not been posted.

SecondaryClinically-driven TLR
Time frame:
Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

Results for this outcome have not been posted.

SecondaryAll-cause Mortality
Time frame:
Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

Results for this outcome have not been posted.

SecondaryCardiovascular Mortality
Time frame:
Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

Results for this outcome have not been posted.

SecondaryMI
Time frame:
Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

Results for this outcome have not been posted.

SecondaryAll TLR
Time frame:
Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

Results for this outcome have not been posted.

SecondaryStent Thrombosis
Time frame:
Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up

Results for this outcome have not been posted.

SecondaryBleeding
Time frame:
Prior to discharge, at 1, 6, and 12 months

Results for this outcome have not been posted.

Adverse events

Collected over Up to 365 days post procedure. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SELUTION SLR 014 DEB9/210 (4.3%)78/210 (37.1%)27/210 (12.9%)
Standard Of Care5/208 (2.4%)91/208 (43.8%)23/208 (11.1%)
Most frequent serious events
Showing 10 of 164
Most frequent serious events
EventSELUTION SLR 014 DEBStandard Of Care
Angina PectorisCardiac disorders12/21017/208
Acute Myocardial InfarctionCardiac disorders15/21011/208
Angina unstableCardiac disorders8/2104/208
Atrial FibrillationCardiac disorders8/2103/208
Chest painGeneral disorders3/2107/208
Arteriosclerosis coronary arteryCardiac disorders2/2105/208
Ventricular tachycardiaCardiac disorders0/2105/208
Respiratory failureRespiratory, thoracic and mediastinal disorders5/2101/208
Vascular stent stenosisGeneral disorders5/2103/208
Coronary artery diseaseCardiac disorders2/2104/208
Most frequent other events
Most frequent other events
EventSELUTION SLR 014 DEBStandard Of Care
Angina pectorisCardiac disorders19/21019/208
Chest painGeneral disorders11/2106/208

Baseline characteristics

The primary analysis population is Per Protocol. The Per Protocol population is 197 participants for the SELUTION SLR 014 DEB group and 193 participants for the Standard of Care group.

Age, Continuous
Age, Continuous(Years)SELUTION SLR 014 DEBStandard Of CareTotal
Median68 (63 to 75)71 (63 to 76)69 (63 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)SELUTION SLR 014 DEBStandard Of CareTotal
Female365086
Male161143304
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SELUTION SLR 014 DEBStandard Of CareTotal
Hispanic or Latino91524
Not Hispanic or Latino137145282
Unknown or Not Reported513384
Diabetes
Diabetes(Participants)SELUTION SLR 014 DEBStandard Of CareTotal
Count of participants8582167
Hypertension
Hypertension(Participants)SELUTION SLR 014 DEBStandard Of CareTotal
Count of participants183180363
Hypercholesterolemia
Hypercholesterolemia(Participants)SELUTION SLR 014 DEBStandard Of CareTotal
Count of participants179171350
Prior Myocardial Infarction (MI)
Prior Myocardial Infarction (MI)(Participants)SELUTION SLR 014 DEBStandard Of CareTotal
Count of participants9493187
Current smoker
Current smoker(Participants)SELUTION SLR 014 DEBStandard Of CareTotal
Count of participants302757

8 further baseline measures are reported on the registry.

08

Study locations

48 sites
09

References and documents

Publications

  • Cutlip DE, Mehran R, Sharma S, Doros G, Jefferson B, Stefanini G, Dohad S, Neylon A, Ben-Dor I, Patel D, Chehab BM, Pradhan A, Nerla R, Vranckx P, Poulin MF, Jeremias A, Osborn EA, Waksman R; SELUTION4ISR Investigators. Sirolimus-Eluting Balloon vs Repeat Drug-Eluting Stent or Balloon Angioplasty for Coronary In-Stent Restenosis. J Am Coll Cardiol. 2026 Jul 7;88(1):62-72. doi: 10.1016/j.jacc.2026.03.021. Epub 2026 Apr 15. PubMed 41984017 ↗
  • Cutlip DE, Mehran R, Doros G, Kaplinskiy V, Lee J, Zheng L, Kausik M, Osborn E, Waksman R. Prospective randomized single-blind multicenter study to assess the safety and effectiveness of the SELUTION SLR 014 drug eluting balloon in the treatment of subjects with in-stent restenosis: Rationale and design. Am Heart J. 2025 Jun;284:11-19. doi: 10.1016/j.ahj.2025.02.001. Epub 2025 Feb 12. PubMed 39952378 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Aug 2025, 61 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Of 13 interventional studies with no phase under Coronary Restenosis, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 61 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2020
First posted
Feb 21, 2020
StartActual
Jul 6, 2020
Primary completionActual
Aug 15, 2025
CompletionEst.
Aug 2029
Results first posted
Oct 20, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 20, 2026
Sites
7 sites added, 7 sites removed
Show 7 added (4 France, 3 Italy)
  • Clinique Valmy · Dijon, France
  • Hôpital privé Jacques Cartier · Massy, France
  • Clinique Saint Hilaire · Rouen, France
  • CHU Toulouse Rangueil · Toulouse, France
  • Maria Cecilia Hospital · Cotignola, Italy
  • Instituto Clinico Humanitas Milan · Milan, Italy
  • Center Azienda Ospedaliero Universitaria de Padova · Padova, Italy
Show 7 removed
  • Clinique Valmy · Dijon, France
  • Hôpital privé Jacques Cartier · Massy, France
  • Clinique Saint Hilaire · Rouen, France
  • CHU Toulouse Rangueil · Toulouse, France
  • Maria Cecilia Hospital · Cotignola, Italy
  • Instituto Clinico Humanitas Milan · Milan, Italy
  • Center Azienda Ospedaliero Universitaria de Padova · Padova, Italy
Oct 20, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of Participants With Target Lesion Failure (TLF)Time frame: 12 months post-index procedure
Oct 20, 2026
Documents
Secondary outcomes
10 edited, 2 added, 1 removed
What changed in the outcomes
  • EditedDevice successSuccessTime frame: Index Procedure
  • EditedClinically -driven TLR, all TLRTime frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
  • EditedClinically drivenDriven Target Vessel Revascularization (TVR), All TVR, all TVR, nonNon-TVRTime frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
  • EditedNet adverse clinical eventsAdverse Clinical EventsTime frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up → Prior to discharge, at 1, 6, and 12 months
  • EditedBinary angiographic restenosisAngiographic RestenosisTime frame: 12 months
  • EditedIn-stent percent diameter stenosisPercent Diameter StenosisTime frame: 12 months
  • EditedIn-segment percent diameter stenosisPercent Diameter StenosisTime frame: 12 months
  • EditedIn-stent Late Lumen Loss (LLL)Time frame: 12 months
  • EditedIn-stent Minimum Lumen Diameter (MLD)Time frame: 12 months
  • EditedOptical Coherence Tomography (OCT assessment) Assessment of neointimal hyperplasiaNeointimal Hyperplasia, neoNeo-atherosclerosis, and stent malappositionStent MalappositionTime frame: 12 months
  • AddedTarget Vessel Failure (TVF)Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
  • AddedAll TLRTime frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
  • RemovedTVFTime frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Results posted
    7 sites added, 7 sites removed
    Show 7 added (4 France, 3 Italy)
    • Clinique Valmy · Dijon, France
    • Hôpital privé Jacques Cartier · Massy, France
    • Clinique Saint Hilaire · Rouen, France
    • CHU Toulouse Rangueil · Toulouse, France
    • Maria Cecilia Hospital · Cotignola, Italy
    • Instituto Clinico Humanitas Milan · Milan, Italy
    • Center Azienda Ospedaliero Universitaria de Padova · Padova, Italy
    Show 7 removed
    • Clinique Valmy · Dijon, France
    • Hôpital privé Jacques Cartier · Massy, France
    • Clinique Saint Hilaire · Rouen, France
    • CHU Toulouse Rangueil · Toulouse, France
    • Maria Cecilia Hospital · Cotignola, Italy
    • Instituto Clinico Humanitas Milan · Milan, Italy
    • Center Azienda Ospedaliero Universitaria de Padova · Padova, Italy
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of Participants With Target Lesion Failure (TLF)Time frame: 12 months post-index procedure
    Secondary outcomes 10 edited, 2 added, 1 removed
    What changed in the outcomes
    • EditedDevice successSuccessTime frame: Index Procedure
    • EditedClinically -driven TLR, all TLRTime frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
    • EditedClinically drivenDriven Target Vessel Revascularization (TVR), All TVR, all TVR, nonNon-TVRTime frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
    • EditedNet adverse clinical eventsAdverse Clinical EventsTime frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up → Prior to discharge, at 1, 6, and 12 months
    • EditedBinary angiographic restenosisAngiographic RestenosisTime frame: 12 months
    • EditedIn-stent percent diameter stenosisPercent Diameter StenosisTime frame: 12 months
    • EditedIn-segment percent diameter stenosisPercent Diameter StenosisTime frame: 12 months
    • EditedIn-stent Late Lumen Loss (LLL)Time frame: 12 months
    • EditedIn-stent Minimum Lumen Diameter (MLD)Time frame: 12 months
    • EditedOptical Coherence Tomography (OCT assessment) Assessment of neointimal hyperplasiaNeointimal Hyperplasia, neoNeo-atherosclerosis, and stent malappositionStent MalappositionTime frame: 12 months
    • AddedTarget Vessel Failure (TVF)Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
    • AddedAll TLRTime frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
    • RemovedTVFTime frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
    + 5 other changes: verification date, oversight details, description, arm descriptions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04280029
Lead sponsor
M.A. Med Alliance S.A.
Collaborators
IQVIA Pty Ltd, Cordis US Corp.
Responsible party
Sponsor
First posted
Feb 21, 2020
Start date
Jul 6, 2020
Primary completion
Aug 15, 2025
Completion
Aug 2029 (estimated)
Results posted
Oct 20, 2026
Last update
Oct 20, 2026

Study contacts

Donald E Cutlip, MD
principal investigator · Beth Israel Deaconess Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion